Monthly Archives: November 2018

Sparx Therapeutics-News release 2018-11-8

Sparx Therapeutics & KPC Pharmaceutical Sign Agreement for the Development of anti-Claudin 18.2 Antibodies Sparx Therapeutics, Inc. has signed an agreement with KPC Pharmaceutical to discover and develop a monoclonal antibody against Claudin 18.2 with the potential to treat a range of human diseases including gastric cancer. Under the terms of the agreement, Sparx will…
Read more